|
Antiinflammatory effect was studied in a rat carrageenan paw edema (CE) assay at 50 mg/kg
|
Rattus norvegicus
|
63.0
%
|
|
|
Inhibition of PGE-2 production in 3T3 (murine fibroblast) cell culture.
|
None
|
220.0
nM
|
|
|
Inhibition activity against recombinant human Prostaglandin G/H synthase 2
|
None
|
100.0
nM
|
|
|
Compound was tested for antiinflammatory activity and the % inhibition was reported 3 hr after carrageenan injection in the hind paw edema test in rats: dose=80 mg/kg
|
Rattus norvegicus
|
39.0
%
|
|
|
Anti-inflammatory activity at 3h post drug administration using the carrageenan-induced rat paw edema assay
|
Rattus norvegicus
|
43.8
%
|
|
|
Anti-inflammatory activity at 5 hr post drug administration using the carrageenan-induced rat paw edema assay
|
Rattus norvegicus
|
51.7
%
|
|
|
Anti-inflammatory activity (% inhibition of paw swelling)in rat adjuvant arthritis model at 25 mg/kg oral dose
|
Rattus norvegicus
|
73.0
%
|
|
|
Antiinflammatory efficacy is measured by the percent inhibition of paw volume during the 3 week adjuvant arthritis test at 0.278 mM/kg (57.2 mg)
|
Rattus norvegicus
|
56.0
%
|
|
|
Antiinflammatory efficacy is measured by the percent inhibition of paw volume during the 3 week adjuvant arthritis test at 0.55 mM/kg (113 mg)
|
Rattus norvegicus
|
79.0
%
|
|
|
Antiinflammatory efficacy is measured by the percent inhibition of paw volume during the 3 week adjuvant arthritis test; 0.139-40
|
Rattus norvegicus
|
0.139
%
|
|
|
In vivo antiinflammatory activity against rat carrageenan-induced foot paw edema model at 3 hr following a 1 mg/kg oral dose
|
Rattus norvegicus
|
56.2
%
|
|
|
In vivo antiinflammatory activity against rat carrageenan-induced foot paw edema model at 5 hr following a 1 mg/kg oral dose
|
Rattus norvegicus
|
41.5
%
|
|
|
The mean increase in paw volume was compared between drug treated groups and placebo to calculate the percent inhibition in rats at 0.08 mmol/kg by carrageenan Edema Assay; 30-39
|
Rattus norvegicus
|
30.0
%
|
|
|
The percent inhibition was calculated from the average differences in hind paw volume between the adjuvant injected controls and the adjuvant-injected medicated rats at 0.08 mmol/kg; 40-49
|
Rattus norvegicus
|
40.0
%
|
|
|
Tested for % inhibition in carrageenan-induced rat paw adema after intraperitoneal administration of 100 mg/kg dose at 2 hours
|
Rattus norvegicus
|
70.0
%
|
|
|
Tested for % inhibition in carrageenan-induced rat paw adema after intraperitoneal administration of 100 mg/kg dose at 3.5 hours
|
Rattus norvegicus
|
74.0
%
|
|
|
Tested for % inhibition in carrageenan-induced rat paw adema after peroral administration of 100 mg/kg dose at 2 hours
|
Rattus norvegicus
|
62.0
%
|
|
|
Tested for % inhibition in carrageenan-induced rat paw adema after peroral administration of 100 mg/kg dose at 3.5 hours
|
Rattus norvegicus
|
65.0
%
|
|
|
Percent inhibition of paw volume increase in carrageenan-induced rat after a dose of 120 mg/kg was administered and observed after 4 hours of incubation
|
Rattus norvegicus
|
48.5
%
|
|
|
Percent inhibition of paw volume increase in carrageenan-induced rat after a dose of 120 mg/kg was administered and observed after 6 hours of incubation
|
Rattus norvegicus
|
30.3
%
|
|
|
Percent inhibition of paw volume increase in carrageenan-induced rat after a dose of 40 mg/kg was administered and observed after 4 hours of incubation
|
Rattus norvegicus
|
19.6
%
|
|
|
Percent inhibition of paw volume increase in carrageenan-induced rat after a dose of 40 mg/kg was administered and observed after 6 hours of incubation
|
Rattus norvegicus
|
11.7
%
|
|
|
Biological activity against adjuvant-induced arthritis at the dose of 120 mg/kg (p.o.)
|
Rattus norvegicus
|
100.0
%
|
|
|
Biological activity against adjuvant-induced arthritis at the dose of 120 mg/kg (p.o.); 65/57
|
Rattus norvegicus
|
65.0
%
|
|
|
Biological activity against adjuvant-induced arthritis at the dose of 30 mg/kg (p.o.)
|
Rattus norvegicus
|
100.0
%
|
|
|
Biological activity against adjuvant-induced arthritis at the dose of 30 mg/kg (p.o.); 30/30
|
Rattus norvegicus
|
30.0
%
|
|
|
Biological activity against adjuvant-induced arthritis at the dose of 60 mg/kg (p.o.)
|
Rattus norvegicus
|
100.0
%
|
|
|
Biological activity against adjuvant-induced arthritis at the dose of 60 mg/kg (p.o.); 56/61
|
Rattus norvegicus
|
56.0
%
|
|
|
Compound administered intraperitoneally was tested for antiinflammatory activity in carrageenan-induced rat paw edema assay after 2 hours
|
Rattus norvegicus
|
70.0
%
|
|
|
Compound administered intraperitoneally was tested for antiinflammatory activity in carrageenan-induced rat paw edema assay after 3.5 hours
|
Rattus norvegicus
|
74.0
%
|
|
|
Compound administered orally was tested for antiinflammatory activity in carrageenan-induced rat paw edema assay after 2 hours
|
Rattus norvegicus
|
62.0
%
|
|
|
Compound administered orally was tested for antiinflammatory activity in carrageenan-induced rat paw edema assay after 3.5 hours
|
Rattus norvegicus
|
65.0
%
|
|
|
Mild analgesia activity in the THA assay po
|
Rattus norvegicus
|
1.4
%
|
|
|
Anti-inflammatory activity in rat paw edema assay at 75 mg/kg
|
Rattus norvegicus
|
54.5
%
|
|
|
In vitro inhibitory activity against ovine cyclooxygenase-1 (COX-1) at 200 uM; Inactive
|
None
|
50.0
%
|
|
|
inhibition of acute TPA-induced ear swelling in mice on oral administration of 0.1 nmol/kg
|
Mus musculus
|
35.0
%
|
|
|
Percent inhibition of acute TPA-induced ear swelling in mice upon topical application at 2x 100 ug
|
Mus musculus
|
59.0
%
|
|
|
Inhibition of beta amyloid protein 42 in SH-SY5Y cell lines overexpressing SPA4CT at 600 uM
|
Homo sapiens
|
41.0
%
|
|
|
Inhibition of beta amyloid protein 42 in HEK cell lines overexpressing APP695 at 100 uM
|
Homo sapiens
|
28.0
%
|
|
|
Inhibition of COX2 at 30 uM
|
None
|
6.33
%
|
|
|
Antiangiogenic activity against HUVEC cells by tube formation assay at 100 uM
|
Homo sapiens
|
35.0
%
|
|
|
Anti-inflammatory activity against of FCA-induced odema in BALB/c mouse assessed as oedema inhibition at 0.30 mmol/kg, ip
|
Mus musculus
|
53.0
%
|
|
|
Inhibition of Fischer 344 rat brain acetylcholine esterase at 0.6 mM
|
Rattus norvegicus
|
20.0
%
|
|
|
Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw oedema at 70 mg/kg, po after 2 hrs relative to control
|
Rattus norvegicus
|
17.8
%
|
|
|
Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw oedema at 70 mg/kg, po after 3 hrs relative to control
|
Rattus norvegicus
|
30.3
%
|
|
|
Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw oedema at 70 mg/kg, po after 4 hrs relative to control
|
Rattus norvegicus
|
23.9
%
|
|
|
Inhibition of rat liver 3alphaHSD assessed as 5-beta-dihydrocortisone reduction at 1 mM
|
Rattus norvegicus
|
70.5
%
|
|
|
Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po after 3.5 hrs
|
Rattus norvegicus
|
63.2
%
|
|
|
Inhibition of ovine COX2 at 10 uM
|
Ovis aries
|
76.0
%
|
|
|
Inhibition of ovine COX2 at 1 uM
|
Ovis aries
|
87.0
%
|
|
|
Inhibition of ovine COX1 at 10 uM
|
Ovis aries
|
96.0
%
|
|
|
Antiinflammatory activity against carrageenan-induced rat inflammation model assessed as inhibition of paw edema at 327 umol/kg, po after 3 hrs
|
Rattus norvegicus
|
50.0
%
|
|
|
Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 70 mg/kg, po after 4 hrs relative to control
|
Rattus norvegicus
|
92.0
%
|
|
|
Analgesic activity in Swiss mouse assessed as inhibition of acetic acid-induced writhing responses at 70 mg/kg, po after 4 hrs relative to control
|
Mus musculus
|
83.5
%
|
|
|
Inhibition of sheep COX1 at 2.06 ug/mL
|
Ovis aries
|
53.26
%
|
|
|
Inhibition of COX2 synthesis in pig skin
|
Sus scrofa
|
50.0
%
|
|
|
Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy
|
Homo sapiens
|
6.3
%
|
|
|
Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 70 mg/kg, po measured 4 hrs after carrageenan challenge
|
Rattus norvegicus
|
80.38
%
|
|
|
Analgesic activity in Swiss albino mouse assessed as effect on reaction time for tail withdrawal administered at 70 mg/kg, po after 4 hrs by tail immersion method
|
Mus musculus
|
74.1
%
|
|
|
Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw oedema at 100 mg/kg, po measured 0.5 hrs after carrageenan challenge
|
Rattus norvegicus
|
42.15
%
|
|
|
Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw oedema at 100 mg/kg, po measured 1 hr after carrageenan challenge
|
Rattus norvegicus
|
42.3
%
|
|
|
Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw oedema at 100 mg/kg, po measured 2 hrs after carrageenan challenge
|
Rattus norvegicus
|
42.9
%
|
|
|
Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw oedema at 100 mg/kg, po measured 3 hrs after carrageenan challenge
|
Rattus norvegicus
|
60.0
%
|
|
|
Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw oedema at 100 mg/kg, po measured 4 hrs after carrageenan challenge
|
Rattus norvegicus
|
66.14
%
|
|
|
Antiinflammatory activity in Wistar albino rat assessed as inhibition of carrageenan-induced paw oedema at 100 mg/kg, po measured 5 hrs after carrageenan challenge
|
Rattus norvegicus
|
72.86
%
|
|
|
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins before carrageenan challenge measured 3 hrs after post drug dose
|
Rattus norvegicus
|
52.15
%
|
|
|
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins before carrageenan challenge measured 24 hrs after post drug dose
|
Rattus norvegicus
|
35.65
%
|
|
|
Inhibition of COX1 at 10 uM
|
None
|
48.0
%
|
|
|
Inhibition of COX2 at 10 uM
|
None
|
40.0
%
|
|
|
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw odema at 20 mg/kg, po pretreated 30 mins pre-carrageenan challenge measured after 2 hrs
|
Rattus norvegicus
|
80.89
%
|
|
|
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw odema at 20 mg/kg, po pretreated 30 mins pre-carrageenan challenge measured after 3 hrs
|
Rattus norvegicus
|
90.12
%
|
|
|
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw odema at 20 mg/kg, po pretreated 30 mins pre-carrageenan challenge measured after 4 hrs
|
Rattus norvegicus
|
65.45
%
|
|
|
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw odema at 20 mg/kg, po pretreated 30 mins pre-carrageenan challenge measured after 8 hrs
|
Rattus norvegicus
|
46.72
%
|
|
|
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw odema at 20 mg/kg, po pretreated 30 mins pre-carrageenan challenge measured after 12 hrs
|
Rattus norvegicus
|
36.06
%
|
|
|
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw odema at 20 mg/kg, po pretreated 30 mins pre-carrageenan challenge measured after 2 hrs relative to control
|
Rattus norvegicus
|
80.88
%
|
|
|
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw odema at 20 mg/kg, po pretreated 30 mins pre-carrageenan challenge measured after 3 hrs relative to control
|
Rattus norvegicus
|
89.5
%
|
|
|
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 150 mg/kg, po administered 30 mins before carrageenan challenge measured after 0.5 hrs
|
Rattus norvegicus
|
16.7
%
|
|
|
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 150 mg/kg, po administered 30 mins before carrageenan challenge measured after 1 hr
|
Rattus norvegicus
|
16.7
%
|
|
|
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 150 mg/kg, po administered 30 mins before carrageenan challenge measured after 2 hrs
|
Rattus norvegicus
|
45.8
%
|
|
|
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 150 mg/kg, po administered 30 mins before carrageenan challenge measured after 3 hrs
|
Rattus norvegicus
|
62.5
%
|
|
|
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 150 mg/kg, po administered 30 mins before carrageenan challenge measured after 4 hrs
|
Rattus norvegicus
|
50.0
%
|
|
|
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 150 mg/kg, po administered 30 mins before carrageenan challenge measured after 5 hrs
|
Rattus norvegicus
|
41.7
%
|
|
|
Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr prior to carrageenen challenge measured after 3 hrs relative to control
|
Rattus norvegicus
|
70.7
%
|
|
|
Antiinflammatory activity against carrageenan-induced paw edema in Sprague-Dawley rat at 70 mg/kg, po pretreated 1 hr before carrageenan challenge measured after 4 hrs by plethysmometer
|
Rattus norvegicus
|
92.0
%
|
|
|
Analgesic activity in Swiss albino mouse assessed as inhibition of acetic acid-induced writhing response at 70 mg/kg, po pretreated 1 hr before acetic acid challenge
|
Mus musculus
|
83.5
%
|
|
|
Inhibition of FAAH-mediated [3H]AEA hydrolysis in rat brain homogenate by liquid scintillation spectroscopy relative to control
|
Rattus norvegicus
|
100.0
%
|
|
|
Inhibition of FAAH-mediated [3H]AEA hydrolysis in rat brain homogenate at 100 uM in pH 6.0 by liquid scintillation spectroscopy
|
Rattus norvegicus
|
71.0
%
|
|
|
Antiinflammatory activity against Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 0.5 hrs
|
Rattus norvegicus
|
20.0
%
|
|
|
Antiinflammatory activity against Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 1 hrs
|
Rattus norvegicus
|
18.0
%
|
|
|
Antiinflammatory activity against Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 1.5 hrs
|
Rattus norvegicus
|
25.0
%
|
|
|
Antiinflammatory activity against Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 2 hrs
|
Rattus norvegicus
|
36.0
%
|
|
|
Antiinflammatory activity against Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 2.5 hrs
|
Rattus norvegicus
|
39.0
%
|
|
|
Antiinflammatory activity against Wistar albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 3 hrs
|
Rattus norvegicus
|
42.0
%
|
|
|
Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 50 to 70 mg/kg, sc administered 1 hr before carrageenan challenge measured after 1 hr relative to control
|
Rattus norvegicus
|
6.08
%
|
|
|
Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 50 to 70 mg/kg, sc administered 2 hrs before carrageenan challenge measured after 1 hr relative to control
|
Rattus norvegicus
|
45.0
%
|
|
|
Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 50 to 70 mg/kg, sc administered 3 hrs before carrageenan challenge measured after 1 hr relative to control
|
Rattus norvegicus
|
60.66
%
|
|
|
Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 50 to 70 mg/kg, sc administered 4 hrs before carrageenan challenge measured after 1 hr relative to control
|
Rattus norvegicus
|
69.52
%
|
|
|
Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 70 mg/kg, po after 4 hrs
|
Rattus norvegicus
|
82.69
%
|
|
|
Analgesic activity in po dosed mouse assessed as decrease in tail flick tendency after 4 hrs by tail flick test
|
Mus musculus
|
73.52
%
|
|
|
Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 5 hrs before xylene challenge measured after 3 hrs post dose
|
Mus musculus
|
23.39
%
|
|
|
Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 24 hrs before xylene challenge measured after 3 hrs post dose
|
Mus musculus
|
13.18
%
|
|
|
Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 4 hrs before xylene challenge measured after 3 hrs post dose
|
Mus musculus
|
36.33
%
|
|
|
Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 2 hrs before xylene challenge measured after 3 hrs post dose
|
Mus musculus
|
38.58
%
|
|
|
Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 100 mg/kg, ip after 0.5 hrs relative to control
|
Mus musculus
|
61.2
%
|
|
|
Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 1 hr before xylene challenge measured after 3 hrs post dose
|
Mus musculus
|
29.63
%
|
|
|
Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 3 hrs before xylene challenge measured after 3 hrs post dose
|
Mus musculus
|
64.58
%
|
|
|
Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 100 mg/kg, po administered 3 hrs before xylene challenge measured after 3 hrs post dose
|
Mus musculus
|
26.93
%
|
|
|
Antiinflammatory activity against xylene-induced ear edema in Kunming mouse assessed as reduction in ear swelling weight at 100 mg, ip administered 2 hrs post challenge measured after 30 mins
|
Mus musculus
|
51.2
%
|
|
|
Antiinflammatory activity against xylene-induced ear edema in Kunming mouse assessed as reduction in ear swelling thickness at 100 mg, ip administered 2 hrs post challenge measured after 30 mins
|
Mus musculus
|
54.3
%
|
|
|
Antiinflammatory activity in male Sprague-Dawley rat assessed as inhibition of carrageenan-induced rat paw edema dosed subcutaneously equimolar to 70 mg/kg, sc ibuprofen administered 1 hr before carrageenan challenge measured 1 hr post carrageenan challenge relative to control
|
Rattus norvegicus
|
6.08
%
|
|
|
Antiinflammatory activity in male Sprague-Dawley rats assessed as inhibition of carrageenan-induced rat paw edema dosed subcutaneously equimolar to 70 mg/kg, sc ibuprofen administered 1 hr before carrageenan challenge measured 2 hrs post carrageenan challenge relative to control
|
Rattus norvegicus
|
45.0
%
|
|
|
Antiinflammatory activity in male Sprague-Dawley rats assessed as inhibition of carrageenan-induced rat paw edema dosed subcutaneously equimolar to 70 mg/kg, sc ibuprofen administered 1 hr before carrageenan challenge measured 3 hrs post carrageenan challenge relative to control
|
Rattus norvegicus
|
60.66
%
|
|
|
Antiinflammatory activity in male Sprague-Dawley rats assessed as inhibition of carrageenan-induced rat paw edema dosed subcutaneously equimolar to 70 mg/kg, sc ibuprofen administered 1 hr before carrageenan challenge measured 4 hrs post carrageenan challenge relative to control
|
Rattus norvegicus
|
69.52
%
|
|
|
Antiinflammatory activity in albino rat assessed as inhibition of carrageenin-induced paw oedema at 100 mg/kg, po after 3 hrs by plethysmographic analysis relative to control
|
Rattus norvegicus
|
59.5
%
|
|
|
Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced hind paw edema measured after 3 hrs post dose
|
Rattus norvegicus
|
67.4
%
|
|
|
DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid)
|
Homo sapiens
|
212.0
nM
|
|
|
Antiinflammatory activity in Wister albino mouse assessed as inhibition of carrageenan-induced edema after 3 hrs relative to control
|
Mus musculus
|
62.0
%
|
|
|
Antiinflammatory activity in Wister albino mouse assessed as inhibition of carrageenan-induced edema after 2 hrs relative to control
|
Mus musculus
|
59.0
%
|
|
|
Antiinflammatory activity in Wistar CF rat assessed as inhibition of carrageenan-induced paw oedema at 100 mg/kg, po administered 1 hr prior to carrageenan-challenge after 4 hrs (Rvb = 78.14 +/- 7.1 %)
|
Rattus norvegicus
|
43.96
%
|
|
|
Antiinflammatory activity in Wistar CF rat assessed as inhibition of carrageenan-induced paw oedema at 100 mg/kg, po administered 1 hr prior to carrageenan-challenge after 1 hr (Rvb = 55.7 +/- 67.84 %)
|
Rattus norvegicus
|
30.03
%
|
|
|
Antiinflammatory activity in Wistar CF rat assessed as inhibition of carrageenan-induced paw oedema at 100 mg/kg, po administered 1 hr prior to carrageenan-challenge after 2 hrs (Rvb = 68.6 +/- 7.14 %)
|
Rattus norvegicus
|
36.18
%
|
|
|
Antiinflammatory activity in Wistar CF rat assessed as inhibition of carrageenan-induced paw oedema at 100 mg/kg, po administered 1 hr prior to carrageenan-challenge after 3 hrs (Rvb = 74.63 +/- 7.13 %)
|
Rattus norvegicus
|
41.84
%
|
|
|
Antiinflammatory activity in Albino Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 1 hr before carrageenan challenge measured after 3 hrs by plethysmometer
|
Rattus norvegicus
|
69.5
%
|
|
|
Antiinflammatory activity in Albino Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, po administered 1 hr before carrageenan challenge measured after 5 hrs by plethysmometer
|
Rattus norvegicus
|
71.69
%
|
|
|
Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced rat paw oedema at 30 mg/kg, po after 3 hrs
|
Rattus norvegicus
|
18.5
%
|
|
|
Antiinflammatory activity in overnight fasted Kunming mouse assessed as inhibition of xylene-induced ear swelling at 4 mg/kg, ip administered before challenge for 5 days measured 1 hr post xylene challenge
|
Mus musculus
|
8.69
%
|
|
|
Antiinflammatory activity in overnight fasted Kunming mouse assessed as inhibition of xylene-induced ear swelling at 30 mg/kg, ip administered before challenge for 5 days measured 1 hr post xylene challenge
|
Mus musculus
|
39.13
%
|
|
|
Antiinflammatory activity in Kunming mouse assessed as inhibition of xylene-induced auricle tumefaction at 0.2 mmol/kg, po qd administered prior to challenge for 5 days measured 30 mins post challenge
|
Mus musculus
|
32.05
%
|
|
|
Antiinflammatory activity in Wistar rat model assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 5 hrs
|
Rattus norvegicus
|
46.81
%
|
|
|
Antiinflammatory activity in Wistar rat model assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 4 hrs
|
Rattus norvegicus
|
43.97
%
|
|
|
Antiinflammatory activity in Wistar rat model assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 1 hr
|
Rattus norvegicus
|
18.33
%
|
|
|
Antiinflammatory activity in Wistar rat model assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 2 hrs
|
Rattus norvegicus
|
22.12
%
|
|
|
Antiinflammatory activity in Wistar rat model assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 3 hrs
|
Rattus norvegicus
|
40.94
%
|
|
|
Antiinflammatory activity in Wistar rat model assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to carrageenan challenge measured after 6 hrs
|
Rattus norvegicus
|
47.62
%
|
|
|
Antiinflammatory activity in Kunming mouse assessed as inhibition of xylene-induced ear edema at 4 mg/kg, ip for 5 days relative to control
|
Mus musculus
|
8.22
%
|
|
|
Antiinflammatory activity in Kunming mouse assessed as inhibition of xylene-induced ear edema at 30 mg/kg, ip for 5 days relative to control
|
Mus musculus
|
39.13
%
|
|
|
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting
|
Homo sapiens
|
47.3
%
|
|
|
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting
|
Homo sapiens
|
-6.6
%
|
|
|
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting
|
Homo sapiens
|
13.5
%
|
|
|
Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 min before carrageenan challenge measured after 3 hr relative to control
|
Rattus norvegicus
|
42.0
%
|
|
|
Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 min before carrageenan challenge measured after 2.5 hr relative to control
|
Rattus norvegicus
|
39.0
%
|
|
|
Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 min before carrageenan challenge measured after 2 hr relative to control
|
Rattus norvegicus
|
36.0
%
|
|
|
Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 min before carrageenan challenge measured after 1.5 hr relative to control
|
Rattus norvegicus
|
25.0
%
|
|
|
Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 min before carrageenan challenge measured after 1 hr relative to control
|
Rattus norvegicus
|
18.0
%
|
|
|
Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 min before carrageenan challenge measured after 0.5 hr relative to control
|
Rattus norvegicus
|
20.0
%
|
|
|
Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, ip pretreated 30 min prior to carrageenan administration measured 4 hr after carrageenan challenge (Rvb = 0%)
|
Rattus norvegicus
|
76.1
%
|
|
|
Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, ip pretreated 30 min prior to carrageenan administration measured 3 hr after carrageenan challenge (Rvb = 0%)
|
Rattus norvegicus
|
66.65
%
|
|
|
Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, ip pretreated 30 min prior to carrageenan administration measured 2 hr after carrageenan challenge (Rvb = 0%)
|
Rattus norvegicus
|
63.55
%
|
|
|
Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 25 mg/kg, ip pretreated 30 min prior to carrageenan administration measured 1 hr after carrageenan challenge (Rvb = 0%)
|
Rattus norvegicus
|
55.38
%
|
|
|
Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr prior to carrageenan-challenge measured at 2 hr relative to control
|
Rattus norvegicus
|
65.3
%
|
|
|
Anti-inflammatory activity in Charles Foster albino Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered 30 min post carrageenan-challenge measured up to 3 hr relative to control
|
Rattus norvegicus
|
39.0
%
|
|
|
Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered 30 min before carrageenan challenge measured after 1 to 3 hr by plethysmometer analysis
|
Rattus norvegicus
|
39.0
%
|
|
|
Anti-inflammatory activity inRattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered for 30 min followed by carrageenan challenge measured after 1 to 3 hr relative to control
|
Rattus norvegicus
|
39.0
%
|
|
|
Anti-inflammatory activity in Rattus norvegicus Wistar (rat) assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg administered for 1 hr prior to carrageenan challenge measured at 5 hr relative to control
|
Rattus norvegicus
|
76.47
%
|
|
|
Anti-inflammatory activity in Rattus norvegicus Wistar (rat) assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg administered for 1 hr prior to carrageenan challenge measured at 1 hr relative to control
|
Rattus norvegicus
|
62.5
%
|
|
|
Anti-inflammatory activity in Rattus norvegicus albino (rat) assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 to 3 hr prior challenge
|
Rattus norvegicus
|
49.0
%
|
|
|
Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as carrageenan-induced paw edema at 20 mg/kg, po administered 1 hr prior to carrageenan-challenge measured at 3 hr relative to control
|
Rattus norvegicus
|
62.82
%
|
|
|
Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as carrageenan-induced paw edema at 20 mg/kg, po administered 1 hr prior to carrageenan-challenge measured at 2 hr relative to control
|
Rattus norvegicus
|
58.19
%
|
|
|
Anti-inflammatory activity in Rattus norvegicus Wistar albino (rat) assessed as carrageenan-induced paw edema at 20 mg/kg, po administered 1 hr prior to carrageenan-challenge measured at 1 hr relative to control
|
Rattus norvegicus
|
53.93
%
|
|
|
Anti-inflammatory activity in Mus musculus Kunming (mouse) assessed as inhibition of xylene-induced ear edema at 50 mg/kg, po administered 2 hr prior to xylene challenge measured at 2 hr post xylene challenge relative to control
|
Mus musculus
|
19.78
%
|
|
|
Anti-inflammatory activity in Mus musculus Kunming (mouse) assessed as inhibition of xylene-induced ear edema at 100 mg/kg, po administered 2 hr prior to xylene challenge measured at 2 hr post xylene challenge relative to control
|
Mus musculus
|
33.03
%
|
|
|
Anti-inflammatory activity in Mus musculus Kunming (mouse) assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 24 hr prior to xylene challenge measured at 24 hr post xylene challenge relative to control
|
Mus musculus
|
20.59
%
|
|
|
Anti-inflammatory activity in Mus musculus Kunming (mouse) assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 4 hr prior to xylene challenge measured at 4 hr post xylene challenge relative to control
|
Mus musculus
|
30.1
%
|
|
|
Anti-inflammatory activity in Mus musculus Kunming (mouse) assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 3 hr prior to xylene challenge measured at 3 hr post xylene challenge relative to control
|
Mus musculus
|
34.51
%
|
|
|
Anti-inflammatory activity in Mus musculus Kunming (mouse) assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 1 hr prior to xylene challenge measured at 1 hr post xylene challenge relative to control
|
Mus musculus
|
41.62
%
|
|
|
Anti-inflammatory activity in Mus musculus Kunming (mouse) assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 0.5 hr prior to xylene challenge measured at 0.5 hr post xylene challenge relative to control
|
Mus musculus
|
32.54
%
|
|
|
Anti-inflammatory activity in Mus musculus Kunming (mouse) assessed as inhibition of xylene-induced ear edema at 200 mg/kg, po administered 2 hr prior to xylene challenge measured at 2 hr post xylene challenge relative to control
|
Mus musculus
|
53.51
%
|
|
|
Analgesic activity in Mus musculus (mouse) assessed as inhibition of acetic acid-induced writhing at 15 mg/kg, po measured after 5 min for 15 min relative to control
|
Mus musculus
|
62.43
%
|
|
|
Anti-inflammatory activity in Rattus norvegicus Wistar (rat) assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po after 3 hr relative to control
|
Rattus norvegicus
|
82.33
%
|
|
|
Anti-inflammatory activity in Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po treated 60 min prior to carrageenan injection measured after 1 to 5 hr
|
Rattus norvegicus
|
56.0
%
|
|
|
Anti-inflammatory activity in Wistar Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po measured after 3 hr
|
Rattus norvegicus
|
67.14
%
|
|
|
Anti-inflammatory activity in Sprague-Dawley Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 70 mg/kg, sc administered at 1 hr prior to carrageenan injection measured at 4 hr post-carrageenan challenge by water plethysmometer
|
Rattus norvegicus
|
69.52
%
|
|
|
Anti-inflammatory activity in Sprague-Dawley Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 70 mg/kg, sc administered at 1 hr prior to carrageenan injection measured at 3 hr post-carrageenan challenge by water plethysmometer
|
Rattus norvegicus
|
60.66
%
|
|
|
Anti-inflammatory activity in Sprague-Dawley Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 70 mg/kg, sc administered at 1 hr prior to carrageenan injection measured at 2 hr post-carrageenan challenge by water plethysmometer
|
Rattus norvegicus
|
45.0
%
|
|
|
Anti-inflammatory activity in Sprague-Dawley Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema administered at 70 mg/kg, sc at 1 hr prior to carrageenan injection measured at 1 hr post-carrageenan challenge by water plethysmometer
|
Rattus norvegicus
|
6.08
%
|
|
|
Analgesic activity in Swiss albino Mus musculus (mouse) assessed as inhibition of pain at 70 mg/kg, po measured after 4 hr by tail immersion method
|
Mus musculus
|
73.5
%
|
|
|
Anti-inflammatory activity in Wistar Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 70 mg/kg, po administered 1 hr prior to carrageenan-challenge measured after 4 hr by plethysmometer analysis
|
Rattus norvegicus
|
82.69
%
|
|
|
Anti-inflammatory activity in Wistar Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 70 mg/kg, po administered 1 hr prior to carrageenan-challenge measured after 3 hr by plethysmometer analysis
|
Rattus norvegicus
|
78.16
%
|
|
|
Anti-inflammatory activity in Wistar Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 200 mg/kg, po administered 1 hr prior to carrageenan-challenge measured after 3 hr relative to untreated control
|
Rattus norvegicus
|
53.19
%
|
|
|
Anti-inflammatory activity in Kunming Mus musculus (mouse) assessed as inhibition of xylene-induced ear swelling at 200 mg/kg, po administered 1 hr prior to xylene challenge measured after 30 min relative to untreated control
|
Mus musculus
|
40.14
%
|
|
|
Analgesic activity in Kunming Mus musculus (mouse) assessed as inhibition of acetic acid-induced writhing at 200 mg/kg, po administered 1 hr prior to acetic acid challenge measured for 15 min relative to untreated control
|
Mus musculus
|
84.11
%
|
|
|
Antiinflammatory activity in Charles Foster albino rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered 30 mins before carrageenan challenge measured after 1 to 3 hrs by plethysmometer analysis
|
Rattus norvegicus
|
39.0
%
|
|
|
Inhibition of COX-1 in human MDA-MB-231 cells assessed as inhibition of arachidonic acid-induced PGE2 formation at 100 uM incubated for 30 mins prior to arachidonic acid challenge measured after 30 mins by radioimmunoassay relative to vehicle-treated control
|
Homo sapiens
|
70.0
%
|
|
|
Inhibition of COX-1 in human THP1 cells assessed as inhibition of arachidonic acid-induced TXB2 formation at 100 uM incubated for 30 mins prior to arachidonic acid challenge measured after 30 mins by radioimmunoassay relative to vehicle-treated control
|
Homo sapiens
|
90.0
%
|
|
|
Inhibition of COX-1 in human washed platelet assessed as inhibition of 0.5 uM arachidonic acid-induced TXB2 formation incubated for 25 mins prior to arachidonic acid challenge measured after 30 mins by radioimmunoassay
|
Homo sapiens
|
290.0
nM
|
|
|
Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 5 hrs relative to control
|
Rattus norvegicus
|
50.4
%
|
|
|
Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 3 hrs relative to control
|
Rattus norvegicus
|
42.7
%
|
|
|
Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered 1 hr before carrageenan challenge measured after 5 hrs relative to control
|
Rattus norvegicus
|
43.5
%
|
|
|
Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered 1 hr before carrageenan challenge measured after 3 hrs relative to control
|
Rattus norvegicus
|
35.8
%
|
|
|
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 4 hrs relative to control
|
Rattus norvegicus
|
63.3
%
|
|
|
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 3 hrs relative to control
|
Rattus norvegicus
|
72.8
%
|
|
|
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 2 hrs relative to control
|
Rattus norvegicus
|
55.5
%
|
|
|
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 1 hr relative to control
|
Rattus norvegicus
|
42.1
%
|
|
|
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured after 0.5 hrs relative to control
|
Rattus norvegicus
|
40.0
%
|
|
|
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
Cricetulus griseus
|
111.68
%
|
|
|
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
Cricetulus griseus
|
98.25
%
|
|
|
Ex vivo antiplatelet activity in Sprague-Dawley rat assessed as inhibition of collagen-induced platelet aggregation at 10 mg/kg, po after 1 hr
|
Rattus norvegicus
|
10.0
%
|
|
|
Ex vivo antiplatelet activity in Sprague-Dawley rat assessed as inhibition of collagen-induced platelet aggregation at 40 mg/kg, po after 1 hr
|
Rattus norvegicus
|
88.0
%
|
|
|
Inhibition of COX-2 in mouse RAW264.7 cells assessed as decrease in LPS-induced PGE2 production treated prior to LPS challenge by enzyme immunoassay
|
Mus musculus
|
860.0
nM
|
|
|
Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 150 mg/kg
|
Rattus norvegicus
|
56.0
%
|
|
|
Antiinflammatory activity in rabbit assessed as inhibition of edema at 200 ug per site by reversed passive arthus test
|
Oryctolagus cuniculus
|
54.0
%
|
|
|
Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 150 umol/kg, po administered 1 hr before carrageenan challenge measured after 3 hrs
|
Rattus norvegicus
|
32.3
%
|
|
|
Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 150 umol/kg, po administered 1 hr before carrageenan challenge measured after 5 hrs
|
Rattus norvegicus
|
43.5
%
|
|
|
Inhibition of purified ovine COX1 at saturation drug level pre-treated for 1 hr before 10-acetyl-3,7-dihydroxyphenoxazin substrate addition in absence of porcine liver esterase by fluorescence assay
|
Ovis aries
|
100.0
%
|
|
|
Inhibition of human recombinant COX2 at saturation drug level pre-treated for 1 hr before 10-acetyl-3,7-dihydroxyphenoxazin substrate addition in absence of porcine liver esterase by fluorescence assay
|
Homo sapiens
|
100.0
%
|
|
|
Antiinflammatory activity against carrageenan-induced ip dosed Wistar rat paw edema model assessed as inhibition of edema administered 30 mins prior to carrageenan challenge measured after 60 mins
|
Rattus norvegicus
|
53.8
%
|
|
|
Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of LPS-induced paw edema at 150 umol/kg, po administered 1 hr before LPS-stimulation and measured 3 hrs post LPS challenge
|
Rattus norvegicus
|
30.5
%
|
|
|
Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of LPS-induced paw edema at 150 umol/kg, po administered 1 hr before LPS-stimulation and measured 5 hrs post LPS challenge
|
Rattus norvegicus
|
41.4
%
|
|
|
Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 50 mg/kg, ip administered 30 mins before xylene challenge relative to control
|
Mus musculus
|
29.56
%
|
|
|
Antiinflammatory activity in rat assessed as reduction of carrageenan-induced paw oedema at 0.15 mmol/kg, ip administered 5 mins before carrageenan challenge measured after 3.5 hrs
|
Rattus norvegicus
|
36.0
%
|
|
|
Analgesic activity in albino mouse assessed as inhibition of acetic acid-induced writhing response at 1 mmol/kg relative to control
|
Mus musculus
|
69.0
%
|
|
|
Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema relative to control
|
Rattus norvegicus
|
73.0
%
|
|
|
Anti-inflammatory activity in rat assessed as reduction of carrageenan-induced paw edema at 150 umol/kg, ip after 3.5 hrs relative to control
|
Rattus norvegicus
|
36.0
%
|
|
|
Inhibition of human recombinant COX2 at 10 uM by enzyme immunoassay
|
Homo sapiens
|
90.41
%
|
|
|
Inhibition of ovine COX1 at 10 uM by enzyme immunoassay
|
Ovis aries
|
73.29
%
|
|
|
Inhibition of COX in human Mahlavu cells after 48 hrs by fluorometric assay
|
Homo sapiens
|
70.0
%
|
|
|
Inhibition of COX in human HuH7 cells after 48 hrs by fluorometric assay
|
Homo sapiens
|
70.0
%
|
|
|
Antiinflammatory activity in mouse assessed as inhibition of xylene-induced ear edema at 100 mg/kg, ip administered 30 mins before xylene challenge measured after 30 mins relative to DMSO-control
|
Mus musculus
|
87.36
%
|
|
|
Inhibition of COX-mediated PGD2/PGE2 production in arachidonic acid-stimulated RBL1 cells at 10 uM preincubated for 2 hrs followed by A23187 induction for 15 mins by LC/MS/MS analysis relative to control
|
Rattus norvegicus
|
95.0
%
|
|
|
Inhibition of 5-LOX-mediated LTB4 production in arachidonic acid-stimulated RBL1 cells at 10 uM preincubated for 2 hrs followed by A23187 induction for 15 mins by LC/MS/MS analysis relative to control
|
Rattus norvegicus
|
10.0
%
|
|
|
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced Il-1beta secretion measured after 24 hrs by Western blot analysis relatively to control
|
Mus musculus
|
35.0
%
|
|
|
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced COX-2 expression measured after 24 hrs by Western blot analysis relatively to control
|
Mus musculus
|
54.0
%
|
|
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated PGE2 production by ELISA
|
Mus musculus
|
390.0
nM
|
|
|
Inhibition of rat ASIC1a receptor expressed in xenopus lavies oocytes assessed as inhibition of peak current amplitude at 1 mM at pH 6.7 at -40 mV holding potential by two electrode voltage clamp relative to control
|
Rattus norvegicus
|
92.0
%
|
|
|
Antiinflammatory activity in Kunming mouse assessed as inhibition of xylene-induced ear edema at 50 mg/kg, ip pretreated for 30 mins followed by xylene challenge measured after 30 mins relative to control
|
Mus musculus
|
28.13
%
|
|
|
Anti-inflammatory activity in rat assessed as inhibition of cotton pellet-induced granuloma at 100 mg/kg relative to control
|
Rattus norvegicus
|
31.3
%
|
|
|
Inhibition of ovine COX1 at 10 uM using arachidonic acid as substrate preincubated for 120 mins followed by substrate addition measured for 5 secs by chemiluminescence assay relative to control
|
Ovis aries
|
88.0
%
|
|
|
Inhibition of human COX2 at 10 uM using arachidonic acid as substrate preincubated for 120 mins followed by substrate addition measured for 5 secs by chemiluminescence assay relative to control
|
Homo sapiens
|
94.0
%
|
|
|
Anti-inflammatory activity against carrageenan-induced Wistar albino rat paw edema model assessed as inhibition of paw edema at 20 mg/kg, po pretreated for 30 mins followed by carrageenan-challenge measured at 1 hr interval for 3 hrs by plethysmographic method relative to control
|
Rattus norvegicus
|
65.9
%
|
|
|
Inhibition of COX in RBL1 cells assessed as reduction in PGE2/D2 production using A23187-induced arachidonic acid as substrate preincubated for 2 hrs followed by A23187 addition measured after 15 mins by LC-MS/MS analysis
|
Rattus norvegicus
|
600.0
nM
|
|
|
Antiinflammatory activity in mouse assessed as inhibition of para-xylene-induced ear edema at 100 mg/kg, ip administered 30 mins prior to para-xylene challenge measured after 30 mins relative to control
|
Mus musculus
|
25.17
%
|
|
|
Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 70 mg/kg, po pretreated for 1 hr followed by carrageenan challenge and measured after 3 hrs by plethysmometer relative to control
|
Rattus norvegicus
|
30.3
%
|
|
|
Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of carrageenan-induced paw edema at 70 mg/kg, po pretreated for 1 hr followed by carrageenan challenge and measured after 4 hrs by plethysmometer relative to control
|
Rattus norvegicus
|
23.9
%
|
|
|
Analgesic activity in CD1 mouse assessed as inhibition of acetic acid-induced writhings at 10 mg/kg, po pretreated for 30 mins followed by acetic acid challenge for 5 mins and measured for 30 mins relative to control
|
Mus musculus
|
48.01
%
|
|
|
Analgesic activity in CD1 mouse assessed as inhibition of acetic acid-induced writhings at 20 mg/kg, po pretreated for 30 mins followed by acetic acid challenge for 5 mins and measured for 30 mins relative to control
|
Mus musculus
|
52.98
%
|
|
|
Analgesic activity in CD1 mouse assessed as inhibition of acetic acid-induced writhings at 70 mg/kg, po pretreated for 30 mins followed by acetic acid challenge for 5 mins and measured for 30 mins relative to control
|
Mus musculus
|
66.72
%
|
|
|
Antiinflammatory activity in carrageenan-induced paw edema Wistar rat model assessed as protection against edema formation up to 2000 mg/kg, po measured 3 hrs post dose relative to control
|
Rattus norvegicus
|
73.5
%
|
|
|
Inhibition of AKR1C3 (unknown origin) at 6.25 uM using 9,10-phenanthrenequinone as substrate in presence of NADPH by spectrophotometric method relative to control
|
Homo sapiens
|
59.67
%
|
|
|
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600)
|
Staphylococcus aureus subsp. aureus
|
-8.87
%
|
|
|
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600)
|
Escherichia coli
|
0.37
%
|
|
|
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600)
|
Klebsiella pneumoniae
|
-1.68
%
|
|
|
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600)
|
Pseudomonas aeruginosa
|
12.43
%
|
|
|
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600
|
Acinetobacter baumannii
|
9.08
%
|
|
|
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630
|
Candida albicans
|
13.27
%
|
|
|
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570)
|
Cryptococcus neoformans
|
-3.38
%
|
|
|
Antiinflammatory activity in Wistar rat assessed as inhibition of cotton pellet-induced granuloma at 75 mg/kg, po administered daily for 7 days and measured on day 8 relative to control
|
Rattus norvegicus
|
44.6
%
|
|
|
Antiinflammatory activity in Wistar rat model of Freund's adjuvant-induced arthritis assessed as inhibition of arthritis by measuring reduction in paw volume at 75 mg/kg, po administered once daily for 8 days starting from day 7 post Freund's adjuvant treatment and measured after 18 days by mercury plethysmography relative to control
|
Rattus norvegicus
|
29.4
%
|
|
|
Antiinflammatory activity in Swiss mouse assessed as inhibition of TPA-induced ear edema at 1 mg/ear applied topically and measured 4 hrs post-TPA challenge relative to control
|
Mus musculus
|
40.2
%
|
|
|
Anti-inflammatory activity in Wistar rat assessed as inhibition of kaolin paw edema at 50 mg/kg, po dosed 1 hr before kaolin injection and measured 4 hrs after kaolin injection relative to untreated control
|
Rattus norvegicus
|
45.0
%
|
|
|
Inhibition of AChE (unknown origin) at 0.5 mM using acetylcholine iodide as substrate by Ellman method relative to untreated control
|
Homo sapiens
|
61.19
%
|
|
|
Inhibition of BuChE (unknown origin) at 0.5 mM using butyrylthiocholine bromide as substrate by Ellman method relative to untreated control
|
Homo sapiens
|
35.51
%
|
|
|
Antioxidant activity assessed as DPPH free radical scavenging activity at 0.5 mM relative to untreated control
|
None
|
11.33
%
|
|
|
Inhibition of 5-LOX (unknown origin) relative to untreated control
|
Homo sapiens
|
42.5
%
|
|
|
Inhibition of COX1 in human platelet rich plasma in assessed as inhibition of ADP-induced platelet aggregation at 10 uM incubated for 5 mins by turbidimetry based Born's method relative to control
|
Homo sapiens
|
60.0
%
|
|
|
Antiinflammatory activity in Sprague-Dawley rat assessed as reduction in carrageenan induced paw edema at 100 mg/kg, po administered 1 hr before carrageenan challenge measured at 3 hrs post challenge
|
Rattus norvegicus
|
68.0
%
|
|
|
Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of croton oil-induced ear edema at 100 mg/kg, po administered 1 hr before croton oil challenge measured after 3 hrs post challenge
|
Rattus norvegicus
|
78.19
%
|
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
18.98
%
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
15.37
%
|
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
-0.02
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.11
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
-0.02
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.11
%
|
|
|
Inhibition of bovine COX1 at 100 uM using arachidonic acid as substrate preincubated for 5 mins followed by substrate addition and measured after 5 mins by ADPH-based fluorescence assay relative to control
|
Bos taurus
|
56.6
%
|
|
|
Inhibition of human recombinant COX-2 at 100 uM using arachidonic acid as substrate preincubated for 15 mins followed by substrate addition and measured after 5 mins by ADPH-based fluorescence assay relative to control
|
Homo sapiens
|
53.7
%
|
|
|
Inhibition of iNOS in mouse macrophages assessed as reduction in LPS-induced nitric oxide production at 50 uM incubated for overnight by griess assay relative to control
|
Mus musculus
|
82.1
%
|
|
|
Inhibition of iNOS in mouse macrophages assessed as reduction in LPS-induced nitric oxide production at 100 uM incubated for overnight by griess assay relative to control
|
Mus musculus
|
83.7
%
|
|
|
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema formation at 100 mg/kg, po administered 1 hr before carrageenan stimulation and measured after up to 6 hrs relative to control
|
Rattus norvegicus
|
42.0
%
|
|
|
Antibiofilm activity against Staphylococcus aureus CECT 976 preform-matured biofilm assessed as increase in biofilm inactivation at upto 10 times of MIC incubated upto 24 hrs relative to control
|
Staphylococcus aureus
|
80.0
%
|
|
|
Antibiofilm activity against Staphylococcus aureus CECT 976 preform-matured biofilm assessed as increase in biofilm removal at 10 times of MIC incubated for 6 hrs relative to control
|
Staphylococcus aureus
|
39.0
%
|
|
|
Antibiofilm activity against Staphylococcus aureus CECT 976 preform-matured biofilm assessed as increase in biofilm removal at 5 times of MIC incubated for 6 hrs relative to control
|
Staphylococcus aureus
|
42.0
%
|
|
|
Antibiofilm activity against Staphylococcus aureus CECT 976 preform-matured biofilm assessed as increase in biofilm removal at MIC incubated for 6 hrs relative to control
|
Staphylococcus aureus
|
42.0
%
|
|
|
Inhibition of cell adhesion in Staphylococcus aureus CECT 976 assessed as decrease in CFU at 10 times of MIC incubated upto 24 hrs relative to control
|
Staphylococcus aureus
|
100.0
%
|
|
|
Inhibition of cell adhesion in Staphylococcus aureus CECT 976 assessed as decrease in biomass content at upto 10 times of MIC incubated upto 24 hrs relative to control
|
Staphylococcus aureus
|
38.5
%
|
|
|
Inhibition of biofilm formation in Streptococcus pneumoniae incubated for 24 hrs by crystal violet staining based assay relative to control
|
Streptococcus pneumoniae
|
37.0
%
|
|
|
Inhibition of biofilm formation in Escherichia coli incubated for 24 hrs by crystal violet staining based assay relative to control
|
Escherichia coli
|
37.0
%
|
|
|
Inhibition of cell adhesion in Staphylococcus aureus CECT 976 assessed as decrease in CFU at 5 times of MIC incubated upto 24 hrs relative to control
|
Staphylococcus aureus
|
100.0
%
|
|
|
Inhibition of COX-1 (unknown origin) using arachidonic acid as substrate at 1000 uM measured after 10 mins by fluorometric based multimode microplate reader relative to control
|
Homo sapiens
|
98.15
%
|
|
|
Inhibition of COX-1 (unknown origin) using arachidonic acid as substrate at 100 uM measured after 10 mins by fluorometric based multimode microplate reader relative to control
|
Homo sapiens
|
89.36
%
|
|
|
Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate at 1000 uM measured after 10 mins by fluorometric based multimode microplate reader relative to control
|
Homo sapiens
|
98.23
%
|
|
|
Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate at 100 uM measured after 10 mins by fluorometric based multimode microplate reader relative to control
|
Homo sapiens
|
88.16
%
|
|
|
Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate at 10 uM measured after 10 mins by fluorometric based multimode microplate reader relative to control
|
Homo sapiens
|
69.52
%
|
|
|
Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate at 1 uM measured after 10 mins by fluorometric based multimode microplate reader relative to control
|
Homo sapiens
|
36.39
%
|
|
|
Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate at 0.1 uM measured after 10 mins by fluorometric based multimode microplate reader relative to control
|
Homo sapiens
|
29.43
%
|
|
|
Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate at 0.01 uM measured after 10 mins by fluorometric based multimode microplate reader relative to control
|
Homo sapiens
|
24.03
%
|
|
|
Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate at 0.001 uM measured after 10 mins by fluorometric based multimode microplate reader relative to control
|
Homo sapiens
|
17.08
%
|
|
|
Anti-inflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip pretreated for 1 hr followed by carrageenan challenge and measured after 1 hr relative to control (Rvb = 0.00 +/-0.02 %)
|
Rattus norvegicus
|
20.0
%
|
|
|
Anti-inflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip pretreated for 1 hr followed by carrageenan challenge and measured after 2 hr relative to control (Rvb = 0.00 +/-0.03 %)
|
Rattus norvegicus
|
60.0
%
|
|
|
Anti-inflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip pretreated for 1 hr followed by carrageenan challenge and measured after 3 hr relative to control (Rvb = 0.00 +/-0.1 %)
|
Rattus norvegicus
|
65.0
%
|
|
|
Anti-inflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip pretreated for 1 hr followed by carrageenan challenge and measured after 4 hr relative to control (Rvb = 0.00 +/-0.4 %)
|
Rattus norvegicus
|
79.0
%
|
|
|
Anti-inflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip pretreated for 1 hr followed by carrageenan challenge and measured after 24 hr relative to control (Rvb = 0.00 +/-0.3 %)
|
Rattus norvegicus
|
14.0
%
|
|
|
Anti-inflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip pretreated for 1 hr followed by carrageenan challenge and measured after 4 hr relative to indomethacin
|
Rattus norvegicus
|
91.0
%
|
|
